FY2024 Q1 Financial Results Presentation

from the beginning

FY2024 Q1 Financial Results Presentation

Forward Looking Statements

FY2024 Q1 Financial Results

Overview of FY2024 Q1 Results

Revenue

Core Operating Profit

Profit Attributable to Owners of the Company

Business Update

Performance

Other Regional Initiatives

Major Updates on Patent Disputes

R&D Update

5DXd ADCs Update

Establish and expand DXd ADCs to address thebroader spectrum of Breast Cancer

For earlier and broader treatment of HER2 low BC

For earlier and broader treatment of HER2 low BC

Approach to 1L treatment in HER2 positive BC

Addressing additional HER2 expressing solid tumors

Establish and expand DXd ADCs to address the broader spectrum of Lung Cancer

Progress in 2L+ NSCLC treatment

Insight on Dato-DXd combination for 1L NSCLC

New treatment approach for 2L+ EGFR mutated NSCLC

EGFR mutated NSCLC 3L

Clinical and Regulatory Progress

Next Wave Update

Clinical and Regulatory Progress

WCLC/ESMO 2024

WCLC/ESMO 2024 Highlight

News Flow

FY2024 News Flow

Appendix

Revenue: Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

5DXd ADCs Revenue (incl. Forex Impact)

5DXd ADCs Upfront and Milestone Payments

Major R&D Milestones (ENHERTU)

Major R&D Milestones (Dato-DXd)

Major R&D Milestones (HER3 DXd, I DXd , DS 6000)

Major R&D Milestones (Next Wave)

Major R&D Pipeline: 5DXd ADCs

Major R&D Pipeline: Next Wave

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8